Company news

Tango Therapeutics, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Tango Therapeutics to Present at the Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference

January 30, 2024

Tango Therapeutics Announces First Patient Dosed in Phase 1/2 Trial of TNG348 in Patients with BRCA1/2-Mutant and Other HRD+ Cancers

January 2, 2024

Tango Therapeutics to Highlight Preclinical Data on PRMT5 Inhibitors at the Society for Neuro-Oncology (SNO) 28th Annual Meeting

November 12, 2023

Tango Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Highlights

November 7, 2023

Tango Therapeutics to Present at the Jefferies London Healthcare Conference

November 6, 2023

Tango Therapeutics to Highlight Preclinical Data on Precision Oncology Pipeline at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

September 17, 2023

Tango Therapeutics Announces FDA Clearance of Investigational New Drug Application for TNG348, a Novel USP1 Inhibitor for the Treatment of BRCA1/2-mutant and Other HRD+ Cancers

September 5, 2023

Tango Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference

September 4, 2023

Tango Therapeutics Announces Updates to Its Board of Directors

August 28, 2023

Tango Therapeutics Announces $80 million Private Placement Financing

August 9, 2023

Tango Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Highlights

August 6, 2023

Tango Therapeutics Announces First Patient Dosed in TNG260 Phase 1/2 Trial in Patients With STK11-Mutant Cancers

July 23, 2023

Tango Therapeutics Announces First Patient Dosed in TNG462 Phase 1/2 Trial in Patients With MTAP-deleted Solid Tumors

July 9, 2023

Tango Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Highlights

May 8, 2023

Tango Therapeutics Presents Preclinical Data on Precision Oncology Programs at the American Association of Cancer Research 2023 Annual Meeting

April 17, 2023

Tango Therapeutics Announces FDA Clearance of Investigational New Drug Application for TNG260, a First-in-Class CoREST Inhibitor for the Treatment of STK11-Mutant Cancers

April 2, 2023

Tango Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Highlights

March 26, 2023

Tango Therapeutics to Highlight Preclinical Data on Precision Oncology Programs at the American Association of Cancer Research 2023 Annual Meeting

March 13, 2023

Tango Therapeutics Announces Limited Exposure to Silicon Valley Bank

March 9, 2023

Tango Therapeutics Announces Appointment of Adam Crystal, M.D., Ph.D. as President of Research and Development

February 27, 2023

Tango Therapeutics Announces FDA Clearance of Investigational New Drug Application for TNG462; Provides Additional Business Updates

January 24, 2023

Tango Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Highlights

November 9, 2022

Tango Therapeutics Announces Presentation of Preclinical Data on PRMT5 Inhibitors TNG908 and TNG462 in Three Abstracts Accepted at 34th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

October 18, 2022

Tango Therapeutics Announces Presentation of Preclinical Data on TNG260 and Discovery Platform Advances at SITC 37th Annual Meeting

October 4, 2022

Tango Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference

September 5, 2022

Tango Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Highlights

August 9, 2022

Tango Therapeutics to Participate in the 13th Annual Wedbush PacGrow Healthcare Conference

August 1, 2022

Tango Therapeutics Added to Russell 2000®, 3000® and Microcap® Indexes

June 26, 2022

Tango Therapeutics to Participate in the Goldman Sachs 43rd Annual Global Healthcare Conference

June 7, 2022

Tango Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Highlights

May 10, 2022

Tango Therapeutics to Participate in the Guggenheim Synthetic Lethality Day 2022

May 8, 2022

Tango Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Highlights

March 27, 2022

Tango Therapeutics Announces Presentation of Preclinical Data on TNG908, USP1 Inhibitor Program and Discovery Platform in Three Abstracts Accepted at AACR 2022 Annual Meeting

March 7, 2022

Tango Therapeutics Announces Presentation of TNG908 Preclinical Combination Data at 2022 ESMO Targeted Anticancer Therapies Congress

March 2, 2022

Tango Therapeutics Announces Clearance of TNG908 IND by FDA and Recent Pipeline Progress Updates

January 23, 2022

Tango Therapeutics to Participate in the Jefferies London Healthcare Conference

November 10, 2021

Tango Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Highlights

November 8, 2021

Tango Therapeutics Announces Appointment of Dr. Marc Rudoltz as Chief Medical Officer and Doug Barry as General Counsel

October 31, 2021

Tango Therapeutics Announces Presentation of Preclinical Data on Lead Program and Discovery Platform in Five Abstracts Accepted at AACR-NCI-EORTC 2021

September 29, 2021

Tango Therapeutics Debuts as Publicly Traded Precision Oncology Company Focused on the Next Generation of Targeted Cancer Therapies

August 9, 2021

Tango Therapeutics and BCTG Acquisition Corp. Announce Merger Agreement to Create Publicly Listed Precision Medicine Company Focused on the Next Generation of Targeted Cancer Therapies

April 13, 2021

← Newer news releases

Decks

The 5 newest of 16 decks. Every deck is listed under its year.